China rises on biotech risk list as US draft rules threaten Chinese biopharma investments

A recent Signal Survey shows China moving up the biotech industry’s concern list even before the Treasury Department issued draft rules that could curb U.S. investment in Chinese biopharma.

The proposed regulations are designed to limit American capital flowing into China’s biotech sector, reflecting heightened geopolitical scrutiny of cross‑border funding.

Despite the growing apprehension, large pharmaceutical companies are still actively looking for pipeline opportunities in China, indicating that the market remains attractive to big‑pharma investors.

Analysts suggest the regulatory shift could reshape funding strategies and affect valuation models for companies with significant Chinese exposure.